Smith & Nephew PLC
SN.
Company Profile
Business description
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
Contact
Hatters Lane
Building 5, Croxley Park
WatfordHertfordshireWD18 8YE
GBRT: +44 1923477100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
17,000
Stocks News & Analysis
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,953.60 | 67.00 | 0.75% |
| CAC 40 | 8,035.87 | 42.61 | -0.53% |
| DAX 40 | 25,399.21 | 24.79 | 0.10% |
| Dow JONES (US) | 51,349.92 | 131.59 | -0.26% |
| FTSE 100 | 10,636.71 | 48.17 | -0.45% |
| HKSE | 24,513.14 | 10.43 | -0.04% |
| NASDAQ | 26,797.54 | 22.84 | -0.09% |
| Nikkei 225 | 66,595.07 | 1,113.80 | 1.70% |
| NZX 50 Index | 13,823.68 | 140.05 | 1.02% |
| S&P 500 | 7,670.84 | 12.85 | -0.17% |
| S&P/ASX 200 | 8,774.60 | 65.30 | 0.75% |
| SSE Composite Index | 3,840.83 | 10.38 | 0.27% |